Ratings UnitedHealth Group Inc.

Equities

UNH

US91324P1021

Market Closed - Nyse Other stock markets 04:00:01 2024-04-26 pm EDT			5-day change	1st Jan Change
495.4 ^USD	+0.30%		-1.15%	-5.91%

Apr. 26	HCA beats first-quarter profit estimates on higher patient admissions	RE
Apr. 23	Sector Update: Health Care Stocks Rise Late Afternoon	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last few months, analysts have been revising downwards their earnings forecast.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Managed Healthcare

	1st Jan change	Capi.	ESG Refinitiv
UNITEDHEALTH GROUP INC.	-5.91%	456B	B-
ELEVANCE HEALTH, INC.	+13.93%	125B	A-
CIGNA	+18.37%	101B	B-
CENTENE CORPORATION	-0.28%	39.69B	B-
HUMANA INC.	-33.18%	36.86B	A-
MOLINA HEALTHCARE, INC.	-5.28%	20.05B	B-
PROGYNY, INC.	-13.82%	3.08B	C+
ALIGNMENT HEALTHCARE, INC.	-39.49%	993M	B-
CLOVER HEALTH INVESTMENTS, CORP.	-28.58%	337M	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes